Corbus Pharmaceuticals Holdings, Inc.

Dose first patient in TEMPO-1 registrational study for oropharyngeal cancer

Deadline passed; outcome being checked

Announced: 14 Sep 2026
Due: 30 Sep 2026
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“First patient in TEMPO-1 registrational 2L study — Sept. 2026”

SourceCorbus Pharmaceuticals Holdings, Inc. Form 8-K press release, 2026-09-14
FilingSEC filing index
Deadline as statedSept. 2026
Deadline used30 Sep 2026, the last day of the stated period
TypeProject
Permanent referenceKI-C-2026-CRBP-000673
Cite as https://keptindex.org/c/KI-C-2026-CRBP-000673/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Dose

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedRecorded from the company's filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Corbus Pharmaceuticals Holdings, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-CRBP-000673 · Corrections policy